23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8150951-23andme-genetic-study-depression-bipolar-disorders/
The U.S. workforce is changing and, with it, so are the ways in which employees are being relocated for companies across the United States. Cartus Corporation, a leading provider of global relocation services, recently released its 2017 Domestic U.S. Relocation Policy and Practices Survey results, a report that examines the responses of 141 mobility managers representing more than 10 million employees. While the overall survey explores trends in how companies are supporting home sale for transferring employees, responding to a growing rental population, and developing intern programs, the primary finding is the identification of a changing pattern in employee relocation, in which an increasing demand for flexibility is translating into different types of work transfers.
To view the multimedia release go to:
https://www.multivu.com/players/English/8035752-new-cartus-survey-shows-employee-relocation-trends/
Oura Health, the Finnish health technology company behind the Oura ring, has moved its total private funding to 12.5M€ after the closure of a round led by US-based Bold Capital Partners and Finland’s Tesi. The funding will be used to scale US market operations and push the Oura platform forward.
The Oura ring and app guides wearers towards better sleep, recovery and readiness to perform by analyzing the body’s sleep, activity levels, daily rhythms and physiological responses.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8362451-oura-health-strengthens-position-us-market/
